ANI Pharmaceuticals, Inc. announced the receipt of FDA approval for its pimozide ANDA, granting the company access to the established antipsychotic market. This generic launch is anticipated to capture significant share from the branded equivalent, creating an additional revenue driver that positions the firm to gain volume and boost earnings.